Published in J Clin Oncol on March 14, 2011
Default Options to Reduce Unnecessary Daily Imaging During Palliative Radiation | NCT03110692
Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA (2012) 5.90
Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity. J Natl Cancer Inst (2012) 3.72
Growth of high-cost intensity-modulated radiotherapy for prostate cancer raises concerns about overuse. Health Aff (Millwood) (2012) 2.67
The relationship between clinical benefit and receipt of curative therapy for prostate cancer. Arch Intern Med (2012) 2.48
Delivering high-quality and affordable care throughout the cancer care continuum. J Clin Oncol (2013) 2.39
Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis. BJU Int (2012) 2.37
Active surveillance for prostate cancer compared with immediate treatment: an economic analysis. Cancer (2011) 2.36
Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer. Cancer (2013) 2.10
Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer. Cancer (2016) 2.02
Understanding regional variation in Medicare expenditures for initial episodes of prostate cancer care. Med Care (2014) 1.50
Racial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer. JAMA Oncol (2016) 1.49
Certificate of need regulations and the diffusion of intensity-modulated radiotherapy. Urology (2012) 1.45
Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy. Int J Radiat Oncol Biol Phys (2014) 1.30
Is there such a thing as a cancer treatment that isn't worth its cost? Oncologist (2011) 1.18
Cost-effectiveness analysis of stereotactic body radiation therapy versus intensity-modulated radiation therapy: an emerging initial radiation treatment option for organ-confined prostate cancer. J Oncol Pract (2012) 1.18
Comparative effectiveness of external-beam radiation approaches for prostate cancer. Eur Urol (2012) 1.17
Intensity modulated radiotherapy for stage III non-small cell lung cancer in the United States: predictors of use and association with toxicities. Lung Cancer (2013) 1.07
Changes in initial treatment for prostate cancer among Medicare beneficiaries, 1999-2007. Int J Radiat Oncol Biol Phys (2012) 1.05
Combining advanced radiotherapy technologies to maximize safety and tumor control probability in stage III non-small cell lung cancer. Strahlenther Onkol (2012) 1.02
Impact of diagnosis and treatment of clinically localized prostate cancer on health-related quality of life for older Americans: a population-based study. Cancer (2012) 0.97
Radiation-induced acid ceramidase confers prostate cancer resistance and tumor relapse. J Clin Invest (2013) 0.96
Managed care and the diffusion of intensity-modulated radiotherapy for prostate cancer. Urology (2012) 0.95
The rise and fall of prostate brachytherapy: use of brachytherapy for the treatment of localized prostate cancer in the National Cancer Data Base. Cancer (2014) 0.94
Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer. Cancer (2013) 0.94
Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis. BMJ (2016) 0.91
Comparative cost-effectiveness of stereotactic body radiation therapy versus intensity-modulated and proton radiation therapy for localized prostate cancer. Front Oncol (2012) 0.89
Racial disparities in changing to a high-volume urologist among men with localized prostate cancer. Med Care (2011) 0.88
The strategies to control prostate cancer by chemoprevention approaches. Mutat Res (2014) 0.87
Evaluation of Adherence to Quality Measures for Prostate Cancer Radiotherapy in the United States: Results from the Quality Research in Radiation Oncology (QRRO) Survey. Pract Radiat Oncol (2012) 0.86
A snapshot of radiation therapy techniques and technology in Queensland: An aid to mapping undergraduate curriculum. J Med Radiat Sci (2013) 0.86
Molecular mechanisms of silibinin-mediated cancer chemoprevention with major emphasis on prostate cancer. AAPS J (2013) 0.86
The impact of technology diffusion on treatment for prostate cancer. Med Care (2013) 0.85
Costs of medical care after open or minimally invasive prostate cancer surgery: a population-based analysis. Cancer (2011) 0.82
Effect of practice integration between urologists and radiation oncologists on prostate cancer treatment patterns. J Urol (2013) 0.81
Interdiction of sphingolipid metabolism to improve standard cancer therapies. Adv Cancer Res (2013) 0.81
Concern for overtreatment using the AUA/ASTRO guideline on adjuvant radiotherapy after radical prostatectomy. BMC Urol (2014) 0.80
Counterpoint: sowing the seeds of standardized care to reap better patient outcomes. J Oncol Pract (2012) 0.80
Association between hospital case volume and the use of bronchoscopy and esophagoscopy during head and neck cancer diagnostic evaluation. Cancer (2013) 0.78
Regional Cost Variations of Robot-Assisted Radical Prostatectomy Compared With Open Radical Prostatectomy. Clin Genitourin Cancer (2015) 0.78
Propensity score matched comparison of SBRT versus IMRT for the treatment of localized prostate cancer. J Radiat Oncol (2016) 0.78
Oncologists' response to new data regarding the use of epidermal growth factor receptor inhibitors in colorectal cancer. J Oncol Pract (2014) 0.78
The war on cancer: progress at what price? J Clin Oncol (2011) 0.78
Local coverage determination policy and the use of stereotactic body radiation therapy for prostate cancer. Urol Pract (2015) 0.77
Treatment-related complications of radiation therapy after radical prostatectomy: comparative effectiveness of intensity-modulated versus conformal radiation therapy. Cancer Med (2014) 0.77
Risk of second cancers according to radiation therapy technique and modality in prostate cancer survivors. Int J Radiat Oncol Biol Phys (2015) 0.76
Racial Differences in Diffusion of Intensity-Modulated Radiation Therapy for Localized Prostate Cancer. Am J Mens Health (2015) 0.75
Prostate cancer: new types of radiotherapy improve cancer outcome but at what cost? Nat Rev Urol (2012) 0.75
Prostate cancer: What is the cost of modern cancer treatment? Nat Rev Urol (2011) 0.75
Patients' Survival Expectations With and Without Their Chosen Treatment for Prostate Cancer. Ann Fam Med (2016) 0.75
Prostate cancer: Interpreting cost-utility analysis of prostate cancer treatment. Nat Rev Urol (2013) 0.75
Utilization of prostate brachytherapy for low risk prostate cancer: Is the decline overstated? J Contemp Brachytherapy (2016) 0.75
Locoregional prostate cancer treatment pattern variation in independent cancer centers: policy effect, patient preference, or physician incentive? Health Serv Insights (2015) 0.75
Direct cost for initial management of prostate cancer: a systematic review. Curr Oncol (2013) 0.75
Managed care and the dissemination of robotic prostatectomy. Surg Innov (2014) 0.75
The cost of cancer-related physician services to Medicare. Yale J Biol Med (2015) 0.75
Chemotherapy use and adoption of new agents is affected by age and comorbidities in patients with metastatic colorectal cancer. Cancer (2016) 0.75
Urological cancer: For localized prostate cancer, does technology equal progress? Nat Rev Clin Oncol (2012) 0.75
Three-dimensional conformal planning with low-segment multicriteria intensity modulated radiation therapy optimization. Pract Radiat Oncol (2014) 0.75
The Comparison of Stereotactic Body Radiation Therapy and Intensity-Modulated Radiation Therapy for Prostate Cancer by NCCN Risk Groups. Front Oncol (2016) 0.75
Reimbursement and use of intensity-modulated radiation therapy for prostate cancer. Medicine (Baltimore) (2017) 0.75
Robotic surgery: current perceptions and the clinical evidence. Surg Endosc (2016) 0.75
Sociodemographic disparities in the utilization of proton therapy for prostate cancer at an urban academic center. Adv Radiat Oncol (2017) 0.75
Communicating Value in Health Care Using Radar Charts: A Case Study of Prostate Cancer. J Oncol Pract (2016) 0.75
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57
Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care (2002) 21.63
Development of a comorbidity index using physician claims data. J Clin Epidemiol (2000) 19.31
Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA (2009) 7.25
Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care (2002) 4.88
Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst (2008) 4.53
Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol (2006) 3.12
High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol (2001) 3.06
Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate? J Clin Oncol (2007) 2.96
Cost comparison of robotic, laparoscopic, and open radical prostatectomy for prostate cancer. Eur Urol (2009) 2.76
Health spending projections through 2019: the recession's impact continues. Health Aff (Millwood) (2010) 2.56
Intensity-modulated radiation therapy: supportive data for prostate cancer. Semin Radiat Oncol (2008) 1.91
Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer. Int J Radiat Oncol Biol Phys (2006) 1.61
Trends in treatment costs for localized prostate cancer: the healthy screenee effect. Med Care (2007) 1.38
Physiologic and radiographic evidence of the distal edge of the proton beam in craniospinal irradiation. Int J Radiat Oncol Biol Phys (2007) 1.23
Comparison of late gastrointestinal and genitourinary toxicity of prostate cancer patients undergoing intensity-modulated versus conventional radiotherapy using localized fields. Prostate Cancer Prostatic Dis (2006) 1.22
Proton-beam vs intensity-modulated radiation therapy. Which is best for treating prostate cancer? Oncology (Williston Park) (2008) 1.01
A surgical safety checklist to reduce morbidity and mortality in a global population. N Engl J Med (2009) 25.01
An estimation of the global volume of surgery: a modelling strategy based on available data. Lancet (2008) 14.07
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 12.74
Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med (2013) 10.74
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol (2009) 8.16
Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA (2011) 7.61
Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA (2009) 7.25
Marital status and survival in patients with cancer. J Clin Oncol (2013) 5.82
The intensity and variation of surgical care at the end of life: a retrospective cohort study. Lancet (2011) 4.44
Utilization and outcomes of minimally invasive radical prostatectomy. J Clin Oncol (2008) 4.23
Simulation-based trial of surgical-crisis checklists. N Engl J Med (2013) 4.14
The reliability of medical record review for estimating adverse event rates. Ann Intern Med (2002) 4.02
Global operating theatre distribution and pulse oximetry supply: an estimation from reported data. Lancet (2010) 3.84
The digital divide in adoption and use of a personal health record. Arch Intern Med (2011) 3.69
Association between congenital cardiovascular malformations and neuroblastoma. J Pediatr (2004) 3.55
Changes in medical errors after implementation of a handoff program. N Engl J Med (2014) 3.50
The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med (2004) 3.50
Crisis checklists for the operating room: development and pilot testing. J Am Coll Surg (2011) 3.19
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol (2013) 3.19
Patterns of communication breakdowns resulting in injury to surgical patients. J Am Coll Surg (2007) 3.09
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Use, costs and comparative effectiveness of robotic assisted, laparoscopic and open urological surgery. J Urol (2012) 2.94
Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol (2005) 2.85
Nomogram to predict the benefit of radiation for older patients with breast cancer treated with conservative surgery. J Clin Oncol (2012) 2.85
Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncol (2012) 2.84
Hospital volume, utilization, costs and outcomes of robot-assisted laparoscopic radical prostatectomy. J Urol (2012) 2.79
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov (2014) 2.79
Comparative effectiveness of perineal versus retropubic and minimally invasive radical prostatectomy. J Urol (2010) 2.77
Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol (2004) 2.68
Economic costs of overactive bladder in the United States. Urology (2009) 2.68
Rates of medical errors and preventable adverse events among hospitalized children following implementation of a resident handoff bundle. JAMA (2013) 2.52
Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. Lancet Oncol (2012) 2.44
NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw (2009) 2.40
Delivering high-quality and affordable care throughout the cancer care continuum. J Clin Oncol (2013) 2.39
Influence of surgeon and hospital volume on radical prostatectomy costs. J Urol (2012) 2.37
Prospective evaluation of analgesic use and risk of renal cell cancer. Arch Intern Med (2011) 2.34
Radical retropubic prostatectomy and robotic-assisted laparoscopic prostatectomy: likelihood of positive surgical margin(s). Urology (2010) 2.31
Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group. Clin Cancer Res (2011) 2.27
Thermal ablation vs surgery for localized kidney cancer: a Surveillance, Epidemiology, and End Results (SEER) database analysis. Urology (2011) 2.24
Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol (2006) 2.23
Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol (2009) 2.23
Robot-assisted versus open radical prostatectomy: the differential effect of regionalization, procedure volume and operative approach. J Urol (2012) 2.22
Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol (2010) 2.18
Changes in safety attitude and relationship to decreased postoperative morbidity and mortality following implementation of a checklist-based surgical safety intervention. BMJ Qual Saf (2011) 2.16
Risks of complications by attending physicians after performing nighttime procedures. JAMA (2009) 2.16
Effect of a 19-item surgical safety checklist during urgent operations in a global patient population. Ann Surg (2010) 2.14
Radical prostatectomy vs radiotherapy vs observation among older patients with clinically localized prostate cancer: a comparative effectiveness evaluation. BJU Int (2013) 2.12
Stepwise approach for nerve sparing without countertraction during robot-assisted radical prostatectomy: technique and outcomes. Eur Urol (2011) 2.09
Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis. BJU Int (2011) 2.07
Comparison of outpatient narcotic prescribing patterns after minimally invasive versus retropubic and perineal radical prostatectomy. J Urol (2011) 2.05
Endorectal magnetic resonance imaging for predicting pathologic T3 disease in Gleason score 7 prostate cancer: implications for prostate brachytherapy. Brachytherapy (2012) 2.05
Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone. Urology (2013) 2.04
Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. J Clin Oncol (2011) 2.02
Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis. J Clin Oncol (2012) 2.00
NCCN clinical practice guidelines in oncology: testicular cancer. J Natl Compr Canc Netw (2009) 1.86
Comparative analysis of outcomes and costs following open radical cystectomy versus robot-assisted laparoscopic radical cystectomy: results from the US Nationwide Inpatient Sample. Eur Urol (2012) 1.86
Utilization and expense of adjuvant cancer therapies following radical prostatectomy. Cancer (2011) 1.85
Which patients with undetectable PSA levels 5 years after radical prostatectomy are still at risk of recurrence?--implications for a risk-adapted follow-up strategy. Urology (2010) 1.83
Suggested objective performance goals and clinical trial design for evaluating catheter-based treatment of critical limb ischemia. J Vasc Surg (2009) 1.81
Lack of insurance negatively affects trauma mortality in US children. J Pediatr Surg (2009) 1.79
Factors associated with the adoption of minimally invasive radical prostatectomy in the United States. J Urol (2012) 1.78
Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol (2002) 1.78
Association between a DASH-like diet and mortality in adults with hypertension: findings from a population-based follow-up study. Am J Hypertens (2009) 1.76
Temporal national trends of minimally invasive and retropubic radical prostatectomy outcomes from 2003 to 2007: results from the 100% Medicare sample. Eur Urol (2011) 1.76
Surgical outcome measurement for a global patient population: validation of the Surgical Apgar Score in 8 countries. Surgery (2011) 1.74
Comparative effectiveness of robot-assisted and open radical prostatectomy in the postdissemination era. J Clin Oncol (2014) 1.74
Logistic regression with incomplete covariate data in complex survey sampling: application of reweighted estimating equations. Epidemiology (2009) 1.73
Comparative effectiveness, costs and trends in treatment of small renal masses from 2005 to 2007. BJU Int (2013) 1.73